Back to search

University of Ioannina

Μελέτη του ρόλου των σηματοδοτικών πορειών του NF-κΒ στην καρκινογένεση του πνεύμονα και στη ρύθμιση γονιδίων-στόχων τους

Abstract

dc:description

Lung cancer is the most common type of cancer and the leading cause of cancer related deaths worldwide. It is clinically divided into non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) that account for ~85% and ~15% of all cases respectively. Lung adenocarcinoma (LUAD), the main histopathological subtype of NSCLC (~55%), develops in distinct steps involving oncogenic mutations that activate the canonical IKKβ-p65/p50 pathway. The canonical NF-κΒ pathway is normally involved in the regulation of pro-inflammatory and stress cellular responses, however it is found aberrantly activated in many cancer types, including NSCLC, promoting tumor growth. However, the molecular mechanisms that govern its role in lung cancer progression are not fully understood. On the contrary, the role of the non canonical NF-κB activation pathway, mediated through IKKα kinase, IKKα-RelB/p52 seems to either promote or inhibit tumor progression in different types of cancers while its role in lung cancer remains understudied. Importantly, both IKKα and ΙΚΚβ kinases can have independent functions of NF-κΒ activation. While IKKβ promotes NSCLC progression, the role of IKKα seems to be tumor suppressive in some types of cancer and tumor promoting in others, while its role in lung cancer progression is still unclear.The aim of the present study was the investigation of the role of both canonical and non-canonical NF-κB activation pathways in NSCLC progression and the identification of novel target genes and possible molecular pathways through which they mediate their effects. To study the role of non canonical NF-κB activation pathway in NSCLC we used human NSCLC cancer cell lines where we stably knocked-down either IKKα kinase or the p52 NF-κB subunit. The generated cell lines were subcutaneously inoculated in immune-compromised NSG mice to grow as in vivo xenografts. The results showed that while IKKα acts to suppress NSCLC growth, p52 subunits enhances tumor formation, and therefore IKKα in NSCLC acts as a tumor suppressor independently of NF-κB activation. These findings were also verified in a bi-transgenic in vivo mouse model where IKKα ablation in alveolar type II cells resulted in the formation of more tumors and of greater size in the mice lungs upon administration of the chemical carcinogen urethane. In order to study the molecular mechanism through which IKKα suppresses lung cancer development we performed RNA-seq analysis in RNA samples from the dissected tumors from both the bi-transgenic mice and the in vivo xenografts, so as to identify novel IKKα target genes. IKKα led to the downregulation of HIF-1α target genes including GAPDH, GPI, PFKL, SLC2A1 and HIGD2A. Our results identified an evolutionary conserved, tumor suppressive mechanism through which IKKα prevents stabilization and activation of HIF-1α transcription factor and subsequent activation of its target genes SLC2A1 και ΗΚ2 in vivo, therefore preventing cancer cell proliferation under hypoxia.To study the role of canonical NF-κB activation pathway in NSCLC, we knocked-down the NF-κΒ subunit RelA/p65 in NSCLC cell lines, which were then inoculated in immune-compromised mice and allowed to grow as in vivo xenografts. Downregulation of the RelA/p65 transcription factor resulted in significantly reduced tumor growth. Total RNA isolated from the tumors that developed, was subjected to RNA-seq analysis. Among the differentially expressed genes identified was the ROS1 proto-oncogene and the LGR6 receptor gene, whose expression was downregulated upon p65 knock-down, while the expression of the cell surface antigen CD82 that acts as a metastasis suppressor was found upregulated. RelA/p65 knock-down or CD82 overexpression was shown to suppress the epithelial-to-mesenchymal cell transition (EMT) by increasing the expression of E-cadherin, the critical marker of the epithelial cell phenotype. Our results showed that RelA/p65 acts to promote NSCLC development through promoting cancer cell migration and epithelial-to-mesenchymal-transition (EMT), at least in part, through downregulation of CD82 expression. Collectively, while IKKα suppresses NSCLC progression through inhibition of HIF-1α transcription factor activation and subsequent regulation of its target genes, the canonical NF-κΒ activation pathway IKKβ-RelA/p65 promotes tumor formation in vivo, in part through downregulation of the CD82 metastasis suppressor.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2020

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Roupakia, Evgenia
  • Ρουπακιά, Ευγενία

Subjects

dc:subject × 25

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/49497

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Roupakia, Evgenia; Ρουπακιά, Ευγενία. Μελέτη του ρόλου των σηματοδοτικών πορειών του NF-κΒ στην καρκινογένεση του πνεύμονα και στη ρύθμιση γονιδίων-στόχων τους. University of Ioannina, 2020. http://hdl.handle.net/10442/hedi/49497